Why the study?
Gastrointestinal bleeding is a common complication of LVAD support, and recent single-center analyses suggested ACEi/ARB and digoxin might prevent it.
Does heart failure drug therapy affect rates of gastrointestinal bleeding in continuous-flow LVAD recipients?
Does heart failure drug therapy affect rates of gastrointestinal bleeding in continuous-flow LVAD recipients?
Answers are grounded in this paper and cite their sources.
Contrary to prior single-center reports, this large registry analysis found no protective effect of ACEi/ARB or digoxin against gastrointestinal bleeding in LVAD recipients, while identifying loop diuretics and PDE5 inhibitors as potential risk factors.
INTRODUCTION: Gastrointestinal bleeding (GIB) remains a common and vexing complication of left ventricular assist device (LVAD) support. Recent single-center analyses suggest that ACE inhibitors (ACEi)/angiotensin receptor blockers (ARB) and digoxin may prevent GIB in LVAD patients. Here we evaluate the effect of guideline-directed medical therapies (GDMT) for heart failure (HF) on rates of GIB through analysis of the INTERMACS registry database. METHODS: Thirteen thousand seven hundred thirty-two patients who received a continuous-flow LVAD and were on antiplatelet therapy and anticoagulation with warfarin after 3 months of pump support were included in the analysis. GIB events following implant were assessed based on receipt of ACEi/ARB, beta-blockers (BB), mineralocorticoid receptor antagonist (MRA), amiodarone, digoxin, loop diuretics, and phosphiesterase-5 inhibitors (PDE5). Backwards stepwise cox regression was used to control for confounding of each drug class on each other, as well as for clinical variables like age, gender, renal function, HF etiology, and device strategy. CONCLUSION: Despite recent reports, ACEi/ARB, MRA, Amio, and digoxin use does not appear to be associated with GIB during LVAD support. The heightened risk seen in those on loop diuretics may reflect venous congestion in these patients, while antiplatelet effects of PDE5 could drive the higher risk of GIB.
No takes yet. Share an insight, caveat, or question.
Jennings et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: